Medindia LOGIN REGISTER
Medindia
Advertisement

Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL

Tuesday, April 18, 2017 Drug News
Advertisement
-- Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: [email protected]

 

Eric Althoff

Novartis Global Media Relations

+41 61 324 7999 (direct)

+41 79 593 4202 (mobile)

[email protected]

Rosemarie Yancosek

Novartis Oncology Communications

1 862-778-9043 (direct)

+1 862-505-9021 (mobile)

[email protected]

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close